Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Epsilon Healthcare Limited ( (AU:EPN) ) is now available.
Epsilon Healthcare reported record quarterly customer receipts of $2.891 million for the December 2025 quarter, a 96% increase on the prior corresponding period, and full-year receipts of $9.175 million, up 71% year-on-year, highlighting a strong turnaround with group revenue now exceeding $1 million per month. The company’s reinstatement to trading on the ASX in December capped a period of operational recovery driven by growth across its CDMO arm, clinics and newly launched pharmacy, supported by an R&D tax incentive and expanding domestic and international client base, positioning Epsilon for scalable growth and a clearer path toward sustainable profitability.
The most recent analyst rating on (AU:EPN) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
More about Epsilon Healthcare Limited
Epsilon Healthcare Limited is an Australian healthcare company focused on natural medicines, active pharmaceutical ingredients and patient-centric wellness services. Its operations span a GMP-compliant contract development and manufacturing business (Epsilon Pharma), clinic services delivered through an integrated telehealth model, and a growing pharmacy arm, targeting both domestic and international markets for compliant pharmaceutical and natural therapy products.
YTD Price Performance: -3.03%
Average Trading Volume: 443,478
Technical Sentiment Signal: Buy
Current Market Cap: A$12.13M
See more insights into EPN stock on TipRanks’ Stock Analysis page.